Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Organovo Holdings Inc

Healthcare US ONVO

NoneUSD
0.00(0%)

Last update at 2025-05-26T14:09:35.560183Z

Day Range

--
LowHigh

52 Week Range

0.852.05
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap12.99M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-19.50100M
  • Revenue TTM0.24M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM -8.51500M
  • Diluted EPS TTM-2.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -17.25700M -11.44600M -16.82400M -18.70800M -26.63200M
Minority interest - - - - -
Net income -17.25900M -11.44800M -16.82600M -18.71000M -26.63500M
Selling general administrative 9.09M 9.63M 15.71M 17.15M 15.13M
Selling and marketing expenses - - - - -
Gross profit 0.37M 1.50M 0.00000M 1.87M 2.61M
Reconciled depreciation 0.29M 0.14M 0.04M 1.14M 0.98M
Ebit -17.73100M -11.47900M -16.82600M -21.47500M -27.27400M
Ebitda -17.45800M -11.33700M -16.76600M -20.97100M -26.23100M
Depreciation and amortization 0.27M 0.14M 0.06M 0.50M 1.04M
Non operating income net other - - - 2.77M 0.64M
Operating income -17.73100M -11.47900M -16.82600M -21.47500M -27.27400M
Other operating expenses 18.10M 12.98M 16.83M 23.67M 30.36M
Interest expense 0.47M 0.00800M 0.02M 3.40M 0.58M
Tax provision 0.00200M 0.00200M 0.00200M 0.00200M 0.00300M
Interest income 0.45M 0.00800M 0.01M 0.59M 0.70M
Net interest income 0.45M 0.00800M 0.01M 0.59M 0.70M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00200M 0.00200M 0.00200M 0.00200M 0.00300M
Total revenue 0.37M 1.50M 0.00000M 2.20M 3.09M
Total operating expenses 18.10M 12.98M 16.83M 23.34M 29.88M
Cost of revenue - - 0.00000M 0.33M 0.48M
Total other income expense net 0.47M 0.03M 0.00200M 2.77M 0.64M
Discontinued operations - - - - -
Net income from continuing ops -17.25900M -11.44800M -16.82600M -18.71000M -26.63500M
Net income applicable to common shares -17.25900M -11.44800M -16.82600M -18.71000M -26.63500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 20.31M 33.30M 39.92M 28.44M 40.62M
Intangible assets - - - 0.12M 0.14M
Earning assets - - - - -
Other current assets 0.89M 0.86M 1.03M 0.85M 1.05M
Total liab 4.98M 3.09M 0.72M 1.81M 4.33M
Total stockholder equity 15.33M 30.21M 39.20M 26.63M 36.30M
Deferred long term liab - - - - 0.59M
Other current liab 2.85M 0.49M 0.44M 1.09M 2.58M
Common stock 0.00900M 0.00900M 0.00900M 0.13M 0.12M
Capital stock 0.00900M 0.00900M 0.00900M 0.13M 0.12M
Retained earnings -324.99800M -307.73900M -296.29100M -279.46500M -260.75500M
Other liab - - - - 0.59M
Good will - - - - -
Other assets 0.65M 0.85M 1.03M - 0.08M
Cash 15.30M 28.68M 37.36M 27.36M 36.48M
Cash and equivalents - - - - -
Total current liabilities 3.67M 1.38M 0.72M 1.81M 3.74M
Current deferred revenue - - - - 0.53M
Net debt -13.49600M -26.49200M -37.36400M -27.35600M -36.47700M
Short term debt 0.49M 0.48M - - -
Short long term debt - - - - -
Short long term debt total 1.80M 2.18M - - -
Other stockholder equity 340.32M 337.94M 335.48M 305.96M 296.93M
Property plant equipment 2.61M 2.81M 0.38M - 1.83M
Total current assets 17.05M 29.53M 38.40M 28.32M 38.57M
Long term investments - - - - -
Net tangible assets 15.32M 30.11M 39.09M 26.63M 36.30M
Short term investments 0.71M - - - -
Net receivables 0.15M - 0.00000M 0.11M 0.56M
Long term debt - - - - -
Inventory - - - 0.00000M 0.49M
Accounts payable 0.33M 0.41M 0.28M 0.72M 0.63M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00200M - -1.00200M -0.41500M -4.58100M
Additional paid in capital - - - - -
Common stock total equity - - 0.00900M 0.13M 0.12M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -279.46500M -260.75500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.66M 0.95M 1.14M 0.12M 0.22M
Deferred long term asset charges - - - - -
Non current assets total 3.27M 3.76M 1.52M 0.12M 2.05M
Capital lease obligations 1.80M 2.18M - - -
Long term debt total - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.96600M -0.40900M -0.39300M 0.75M -0.07600M
Change to liabilities -0.14800M 0.13M -0.43900M -1.36700M -0.62800M
Total cashflows from investing activities -0.96600M -0.40900M -0.39300M 0.75M -0.07600M
Net borrowings - - - - -
Total cash from financing activities 0.00000M 0.20M 23.84M 4.93M 13.15M
Change to operating activities 2.61M 0.46M -1.78500M -1.28800M -0.80000M
Net income -17.25900M -11.44800M -16.82600M -18.71000M -26.63500M
Change in cash -13.37400M -8.65700M 10.12M -9.20000M -7.29700M
Begin period cash flow 28.82M 37.48M 27.36M 36.56M 43.85M
End period cash flow 15.44M 28.82M 37.48M 27.36M 36.56M
Total cash from operating activities -12.40800M -8.45300M -13.32300M -14.88200M -20.37500M
Issuance of capital stock 0.00000M 0.25M 23.80M 5.00M 13.33M
Depreciation 0.29M 0.14M 0.04M 1.14M 0.98M
Other cashflows from investing activities - - - 0.75M 0.00300M
Dividends paid - - - - -
Change to inventory 2.54M - 0.00000M 0.28M 0.35M
Change to account receivables -0.15200M 0.00000M 0.11M 0.39M 0.38M
Sale purchase of stock - 0.00000M -0.00100M 5.00M 13.38M
Other cashflows from financing activities -0.96600M -0.04600M 0.04M -0.06100M -0.17300M
Change to netincome 2.25M 2.26M 5.58M 4.21M 5.26M
Capital expenditures 0.40M 0.41M 0.41M 0.41M 0.08M
Change receivables - - - 0.39M 0.38M
Cash flows other operating - - - -0.82400M -0.08000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -9.20000M -7.29700M
Change in working capital 2.31M 0.60M -2.11300M -0.99800M 0.02M
Stock based compensation 2.38M 2.26M 5.56M 4.11M 5.19M
Other non cash items -0.42500M - 0.02M -0.52500M 0.06M
Free cash flow -12.80400M -8.86200M -13.72800M -14.88200M -20.45400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ONVO
Organovo Holdings Inc		 - -% - - - 41.91 1.64 26.23 -0.3255
NVO
Novo Nordisk A/S		 -1.94 4.52% 41.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.11 4.87% 41.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.87 0.87% 442.96 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -24.11 3.79% 611.34 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Organovo Holdings Inc

11555 Sorrento Valley Road, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Keith E. Murphy Exec. Chairman 1972
Dr. Jeffrey N. Miner Chief Scientific Officer 1962
Mr. Thomas Einar Jurgensen J.D., MS Gen. Counsel & Corp. Sec. 1957
Ms. Vaidehi Joshi Director of Discovery Biology & Director 1986
Mr. Thomas P. Hess CPA, MBA Pres & CFO 1964
Dr. Curtis M. Tyree Ph.D. Sr. VP of Strategy & Bus. Devel. NA
Mr. Keith E. Murphy Company Secretary & Executive Chairman 1972
Mr. Thomas P. Hess CPA, MBA President & CFO 1964
Dr. Curtis M. Tyree Ph.D. Senior Vice President of Strategy & Business Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions